Connection

LEI NIE to Drug Resistance, Neoplasm

This is a "connection" page, showing publications LEI NIE has written about Drug Resistance, Neoplasm.
Connection Strength

0.188
  1. Targeting glutaminase is therapeutically effective in ibrutinib-resistant mantle cell lymphoma. Haematologica. 2023 06 01; 108(6):1616-1627.
    View in: PubMed
    Score: 0.081
  2. Targeting PKCd as a Therapeutic Strategy against Heterogeneous Mechanisms of EGFR Inhibitor Resistance in EGFR-Mutant Lung Cancer. Cancer Cell. 2018 12 10; 34(6):954-969.e4.
    View in: PubMed
    Score: 0.059
  3. Cotargeting of BTK and MALT1 overcomes resistance to BTK inhibitors in mantle cell lymphoma. J Clin Invest. 2023 02 01; 133(3).
    View in: PubMed
    Score: 0.020
  4. FDA Approval Summary: Mogamulizumab-kpkc for Mycosis Fungoides and S?zary Syndrome. Clin Cancer Res. 2019 12 15; 25(24):7275-7280.
    View in: PubMed
    Score: 0.015
  5. FDA Drug Approval: Elotuzumab in Combination with Lenalidomide and Dexamethasone for the Treatment of Relapsed or Refractory Multiple Myeloma. Clin Cancer Res. 2017 Nov 15; 23(22):6759-6763.
    View in: PubMed
    Score: 0.013
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.